JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connell, R. J.
Right arrow Articles by De Witt, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connell, R. J.
Right arrow Articles by De Witt, C. C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2003, p. 2153-2155, Vol. 41, No. 5
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.5.2153-2155.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Performance of the OraQuick Rapid Antibody Test for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Patients with Various Levels of Exposure to Highly Active Antiretroviral Therapy

Robert J. O'Connell,1* Teresa M. Merritt,1 Jennifer A. Malia,2 Thomas C. VanCott,3 Matthew J. Dolan,1 Hassan Zahwa,2 William P. Bradley,3 Bernard M. Branson,4 Nelson L. Michael,2 and Caroline C. De Witt1

Wilford Hall Medical Center, Lackland Air Force Base, Texas 78236,1 Division of Retrovirology, Walter Reed Army Institute for Research,2 Henry M. Jackson Foundation, Rockville, Maryland 20850,3 National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 303334

Received 11 July 2002/ Returned for modification 29 November 2002/ Accepted 7 February 2003

With oral mucosal transudate and serum samples from 101 human immunodeficiency virus type 1 (HIV-1)-infected subjects and 100 HIV-1-negative volunteers, the OraQuick HIV-1 test demonstrated 100% specificity and 96% sensitivity. Four false-negative subjects, who were characterized by early initiation of effective antiretroviral therapy, demonstrated waning serum anti-gp41 titers and Western blot band intensities.

* Corresponding author. Mailing address: Department of Infectious Diseases, Wilford Hall Medical Center, 59MDW/MMII, 2200 Bergquist Dr., Ste. 1, Lackland AFB, TX 78236. Phone: (210) 292-2225. Fax: (210) 292-3740. E-mail: robert.oconnell{at}lackland.af.mil.

Journal of Clinical Microbiology, May 2003, p. 2153-2155, Vol. 41, No. 5
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.5.2153-2155.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.